F-star Therapeutics, Inc.
F-star Therapeutics, Inc. (FSTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FSTX · as of Dec 31, 2022
Ownership Breakdown
65
Institutional Holders
▲ 9 vs Q3
$57.84M
Total Inst. Value
▲ $22.34M vs Q3
21.98M
Shares Outstanding
freeFloat 98.18%
9.14M
13F Shares Held
▲ 2.22M vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FSTX largest shareholders · institutional ownership
Q4 2022 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 1.00M | 4.58% | 4.58% | $6.32B | Feb 14, 2023 | NEW |
ROCK SPRINGS CAPITAL MANAGEMENT LP pharmaceutical preparations | 751.9K | 3.44% | 3.44% | $4.75B | Feb 14, 2023 | — held |
TRIUM CAPITAL LLP pharmaceutical preparations | 679.7K | 3.11% | 3.11% | $4.30B | Jan 31, 2023 | NEW |
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC pharmaceutical preparations | 599.5K | 2.74% | 2.74% | $3.79B | Feb 14, 2023 | — held |
DAFNA CAPITAL MANAGEMENT LLC pharmaceutical preparations | 576.9K | 2.64% | 2.64% | $3.65B | Feb 14, 2023 | — held |
ATLAS VENTURE ADVISORS, INC. pharmaceutical preparations | 575.0K | 2.63% | 2.63% | $3.63B | Jan 31, 2023 | — held |
WEISS ASSET MANAGEMENT LP pharmaceutical preparations | 548.2K | 2.51% | 2.51% | $3.46B | Feb 14, 2023 | NEW |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 502.8K | 2.30% | 2.30% | $3.18B | Feb 14, 2023 | NEW |
RUSSELL INVESTMENTS GROUP, LTD. pharmaceutical preparations | 432.1K | 1.98% | 1.98% | $2.73B | Feb 8, 2023 | ▼ 58.6K |
CRYSTALLINE MANAGEMENT INC. pharmaceutical preparations | 375.0K | 1.72% | 1.72% | $2.37B | Mar 13, 2023 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2022 vs prior quarter
Q4 2022
9
Increased
+212.1K shares16
New Positions
first time holders14
Decreased
−357.0K shares0
Sold Out
fully exitedNet shares change (top 50)
144.9K
+212.1K / −357.0K
Net new holders
+11
16 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FSTX insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
42
Sell transactions
0.00
Buy/Sell ratio
$2M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Kayitalire Louis CHIEF MEDICAL OFFICER | Mar 8, 2023 | U-Tender | 29,236 | $7.12 | $208.2K | 25.0K | Form 4 ↗ |
Kayitalire Louis CHIEF MEDICAL OFFICER | Mar 8, 2023 | D-Return | 12,880 | $7.24 | $93.3K | 0 | Form 4 ↗ |
Kayitalire Louis CHIEF MEDICAL OFFICER | Mar 8, 2023 | D-Return | 25,019 | $7.12 | $178.1K | 0 | Form 4 ↗ |
Kayitalire Louis CHIEF MEDICAL OFFICER | Mar 8, 2023 | D-Return | 27,289 | $16.62 | $453.5K | 0 | Form 4 ↗ |
Kayitalire Louis CHIEF MEDICAL OFFICER | Mar 8, 2023 | D-Return | 35,719 | $3.55 | $126.8K | 0 | Form 4 ↗ |
Kayitalire Louis CHIEF MEDICAL OFFICER | Mar 8, 2023 | D-Return | 53,634 | $4.77 | $255.8K | 0 | Form 4 ↗ |
Forster Eliot PRESIDENT AND CEO | Mar 8, 2023 | U-Tender | 347,578 | $7.12 | $2.47M | 74.0K | Form 4 ↗ |
Forster Eliot PRESIDENT AND CEO | Mar 8, 2023 | D-Return | 165,028 | $4.77 | $787.2K | 0 | Form 4 ↗ |
Forster Eliot PRESIDENT AND CEO | Mar 8, 2023 | D-Return | 73,959 | $7.12 | $526.6K | 0 | Form 4 ↗ |
Forster Eliot PRESIDENT AND CEO | Mar 8, 2023 | D-Return | 127,924 | $7.24 | $926.2K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
F-star Therapeutics, Inc. (FSTX) is primarily owned by institutional investors, who hold approximately 41.6% of total shares outstanding. Company insiders own approximately 1.82%, while retail and public investors account for the remaining 56.58%.
The largest institutional shareholder of F-star Therapeutics, Inc. is ARMISTICE CAPITAL, LLC, holding approximately 1.00 million shares — equal to 4.58% of outstanding shares — as of December 31, 2022.
A total of 65 institutional investors currently hold FSTX stock, with a combined institutional value of approximately $57,836,637 as of the most recent 13F filing period.
Frequently asked questions
FSTX ownershipF-star Therapeutics, Inc. (FSTX) is primarily owned by institutional investors, who hold approximately 41.6% of shares. The largest shareholder is ARMISTICE CAPITAL, LLC with a 4.58% stake. Company insiders hold 1.82%. Data sourced from SEC Form 13F as of December 31, 2022.